In the capitalist society, there is a problem with the accessibility of quality medicine to all. People who need some specific type of remedy cannot receive the proper treatment because of merely having not enough money. As a result, the instances of failed treatment are growing every day and pose a problem for society, especially when dealing with contagious diseases. Hence, the issue needs to be addressed adequately without harming healthcare economics and providing a decision for the population’s medical safety.
There is a proposed health policy that considers this problem in our society. The bill H.R. 987 (2019) “Strengthening health care and lowering prescription drug costs act” intends to increase healthcare access and reduce the prescribed medication prices. The primary objects for the effect of this bill are the health insurance and the drug pricing policy. There are seven bills in the given document, three for the former question, and four addressing the latter (H.R. 987, 2019). The method for the solution of the problem is the prohibition of the monopoly of individual pharmaceutical companies for the drug, and stimulation of the development of generic alternatives.
I believe that the proposed bill has strong evidence for it. Primarily, it is ineffective for the modern healthcare system if there is no evidence for the efficacy of the medication. The big data in the form of reliable statistics for improvement can be available only if the individual patients have access to the medicines for the needed time (Sacristán & Dilla, 2015). Next, increasing the number of drug providers can result in successfully addressing the problems of invalid and impaired people in society. This effect shows the importance of adopting the policy to increase life quality in the community (Tummers & Bekkers, 2014). As a result, it is reliable and reasonable legislation to be taken by Congress.
References
Tummers, L., & Bekkers, V. (2014). Policy implementation, street level bureaucracy, and the importance of discretion. Public Management Review, 16(4), 527–547. Web.
Sacristán, J., & Dilla, T. D. (2015). No big data without small data: Learning health care systems begin and end with the individual patient. Journal of Evaluation in Clinical Practice, 21(6), 1014–1017. Web.
Strengthening Health Care and Lowering Prescription Drug Costs Act, H.R.987, 116h Cong. (2019).